Abstract
Background
Whether anticoagulants other than unfractionated heparin are able to suppress cardiac PET uptake of 2-deoxy-2-[18F]-fluoro-D-glucose (18F-FDG) is unknown.
Methods
One-hundred-seventy-four patients without history and clinical evidence of cardiac dysfunction and/or coronary heart disease underwent a 18F-FDG PET/CT study. All patients were studied with a >12-hours fasting and divided into 2 groups: group-1 without anticoagulant therapy (n:75); group-2 patients on low molecular weight heparin (n:60) or warfarin therapy (n:39). Cardiac 18F-FDG uptake was estimated qualitatively using a 4-point scale and semiquantitatively as total LV glycolysis (LVG) and metabolic volume (MV), drawing isocontour volume of interest (VOI) including the whole LV.
Results
Qualitatively, LV 18-FDG uptake was scored 0 or 1, indicating a good suppression, in 10/75 (13%) patients of group-1 and 77/99 (78%) of group-2 (p < .001). Semiquantitatively, patients of group-1 showed higher values of 18-FDG uptake than patients of group-2, assessed as LVG (802,649 ± 468,442 vs 198,989 ± 261,439, p < .0001) or MV (219 ± 77 vs 57 ± 48 cm3, p < .0001). Subanalysis for anticoagulant drugs showed similar results.
Conclusions
Prolonged fasting combined to anticoagulants other than unfractionated heparin is able to minimize glucose cardiac metabolism. Our data confirm previous observation on the possibility to influence the metabolic pattern of the heart before the PET scan and broadens the spectrum of pharmacological options.
Similar content being viewed by others
Abbreviations
- PET:
-
Positron emission tomography
- 18F-FDG:
-
2-deoxy-2-[18F]-fluoro-D-glucose
- LV:
-
Left ventricle
- SUVmax and SUVmean:
-
Standardized uptake value max and mean
- MV:
-
Metabolic LV total volume
- LVG:
-
Total LV glycolysis
- LMWH:
-
Low molecular weight heparin
- WF:
-
Warfarin
References
Ogawa M, Ishino S, Mukai T, Asano D, Teramoto N, Watabe H, et al. 18F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging Study. J Nucl Med 2004;45:1245-50.
Iozzo P, Chareonthaitawee P, Di Terlizzi M, Betteridge DJ, Ferrannini E, Camici PG. Regional myocardial blood flow and glucose utilization during fasting and physiological hyperinsulinemia in humans. Am J Physiol Endocrinol Metab 2002;282:E1163-71.
Maurer AH, Burshteyn M, Adler LP, Gaughan JP, Steiner RM. Variable cardiac 18 FDG patterns seen in oncologic positron emission tomography computed tomography: importance for differentiating normal physiology from cardiac and paracardiac disease. J Thorac Imaging 2012;27:263-8.
Inglese E, Leva L, Matheoud R, Sacchetti G, Secco C, Gandolfo P, et al. Spatial and temporal heterogeneity of regional myocardial uptake in patients without heart disease under fasting conditions on repeated whole-body 18F-FDG PET/CT. J Nucl Med 2007;48:1662-9.
Ambrosini V, Zompatori M, Fasano L, Nanni C, Nava S, Rubello D, et al. 18F-FDG PET/CT for the assessment of disease extension and activity in patients with sarcoidosis: results of a preliminary prospective study. Clin Nucl Med 2013;38:e171-7.
Harisankar CN, Mittal BR, Agrawal KL, Abrar ML, Bhattacharya A. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG uptake. J Nucl Cardiol 2011;18:926-36.
Manabe O, Yoshinaga K, Ohira H, Masuda A, Sato T, Tsujino I, et al. The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial 18F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis. J Nucl Cardiol 2016;23:244-52.
Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR 2008;190:W151-6.
Wollenweber T, Roentgen P, Schäfer A, Schatka I, Zwadlo C, Brunkhorst T, et al. Characterizing the Inflammatory Tissue Response to Acute Myocardial Infarction by Clinical Multimodality Noninvasive Imaging. Circ Cardiovasc Imaging 2014;7:811-8.
Scholtens AM, Verberne HJ, Budde R, Lam M. Additional heparin pre-administration improves cardiac glucose metabolism suppression over low carbohydrate diet alone in 18F-FDG-PET imaging. J Nucl Med 2016;57:568-73.
Dilsizian V, Bacharach SL, Beanlands RS, Bergmann SR, Delbeke D, Dorbala S, et al. ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. J Nucl Cardiol 2016;23:1187-226.
Fallavollita JA, Luisi AJ Jr, Yun E, Dekemp RA, Canty JM Jr. An abbreviated hyperinsulinemic-euglycemic clamp results in similar myocardial glucose utilization in both diabetic and non-diabetic patients with ischemic cardiomyopathy. J Nucl Cardiol 2010;17:637-45.
Chevreuil O, Hultin M. 0stergaard P, Olivecrona T. Biphasic Effects of low-molecular-weight and conventional heparins on chylomicron clearance in rats. Arterioscler Thromb. 1993;13:1397-403.
Persson E, Nordenström J, Nilsson-Ehle P, Hagenfeldt L, Wahren J. Plasma lipolytic activity and substrate oxidation after intravenous administration of heparin and a low molecular weight heparin fragment. Clin Physiol 1990;10:573-83.
Grosskopf I, Shaish A, Ray A, Harats D, Kamari Y. Low molecular weight heparin-induced increase in chylomicron-remnants clearance, is associated with decreased plasma TNF- α level and increased hepatic lipase activity. Thromb Res 2014;133:688-92.
Meisner H, Taylor S. Antilipolytic effects of chlorophenoxyisobutyrate and warfarin in adipocytes. J Lipid Res 1978;19:1025-31.
Fujiwara S, Amisaki T. Steric and allosteric effects of fatty acids on the binding of warfarin to human serum albumin revealed by molecular dynamics and free energy calculations. Chem Pharm Bull 2011;59:860-7.
Authors’ contributions
AG and DG contributed to the conception, design, analysis, and interpretation of data and manuscript preparation and submission. GM and MM had access to the database of the Institute and provided patient’s selection and clinical information. EF and AB participated to imaging analysis and manuscript preparation. ME and PM participated to the design, data analysis, and revised the manuscript.
Disclosure
The authors Assuero Giorgetti, Gavino Marras, Dario Genovesi, Elena Filidei, Antonio Bottoni, Maurizio Mangione, Michele Emdin, and Paolo Marzullo declare that they have no competing interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Author information
Authors and Affiliations
Corresponding author
Additional information
The authors of this article have provided a PowerPoint file, available for download at SpringerLink, which summarises the contents of the paper and is free for re-use at meetings and presentations. Search for the article DOI on SpringerLink.com.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Giorgetti, A., Marras, G., Genovesi, D. et al. Effect of prolonged fasting and low molecular weight heparin or warfarin therapies on 2-deoxy-2-[18F]-fluoro-D-glucose PET cardiac uptake. J. Nucl. Cardiol. 25, 1364–1371 (2018). https://doi.org/10.1007/s12350-017-0800-8
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12350-017-0800-8